| abstract |
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The invention provides, at least in part, an immune score expression level based on one or more of PD-L1, CXCL9, IFNG, GZMB, CD8A, and PD-1 in a sample obtained from an individual with cancer. Treatment with a PD-L1 axis binding antagonist (eg, PD-L1 binding antagonist (eg, anti-PD-L1 antibody, eg, atezolizumab (MPDL3280A)), or PD-1 binding antagonist (eg, anti-PD-1 antibody)). It is based on the discovery that it can be used in a method to predict the therapeutic efficacy of. [Selection diagram] None |